Q-omics provides the consensus-scored ST6GALNAC1 profile across patient tissues and cancer cell-line models. ST6GALNAC1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ST6GALNAC1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ST6GALNAC1 RNA expression shows 17,800 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, and GBM as cancer lineages where ST6GALNAC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST6GALNAC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST6GALNAC1 survival associations across molecular data types. ST6GALNAC1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST6GALNAC1 RNA expression–survival associations across cancer types. High ST6GALNAC1 expression shows unfavorable associations in MESO, but favorable associations in HNSC, THCA, UCEC, LUSC and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ST6GALNAC1 RNA expression.
This table summarizes ST6GALNAC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ST6GALNAC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST6GALNAC1 shows lower tumor expression in HNSC, COAD, KICH, BRCA and KIRC and higher tumor expression in LUAD. The HNSC box plot shows higher ST6GALNAC1 RNA expression in normal versus tumor tissue (log2 FC = −1.997, t-test p < 0.001).
This table shows molecular features associated with ST6GALNAC1 in patient tissues and cancer cell lines. In patient samples, ST6GALNAC1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ST6GALNAC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
